Portal de Periódicos da CAPES

Intensivierte Konsolidierungstherapie für ALL-Hochrisikopatienten

1988; Karger Publishers; Volume: 11; Issue: 1 Linguagem: Inglês

10.1159/000216474

2296-5262

D. Hoelzer, E. Thiel, H. Löffler, T. Büchner, A. Ganser, Gerhard Heil, E. Kurrle, H. Heimpel, P. Koch, T. Lipp, W. Kaboth, R. Kuse, R. Küchler, H. Sodomann, Georg Maschmeyer, M. Freund, H. Diedrich, A.v. Paleske, J. Weh, Hans-Jochen Kölb, U Müller, K. Bross, G. Fuhr, W. Gassmann, D. Gerecke, M. Kress, F.W. Busch, R.M. Nowrousian, W. Schneider, C. Aul, H. Rühl, H. Bartels, F. Harms, A. Weiss, B. Löffler, W. M. Glöckner, H. Füller, H. Pralle, Anthony D. Ho, B. Bonfert, Bertold Emmerich, D. Braumann, M. Brenner-Serke, M. Planker, Kurt Straíf, Pierre Meyer, Richard Greil, S. Petsch, C Görg, Andreas Grüneisen, H.A. Vaupel, H. Bodenstein, Friedrich Overkamp, G. Schlimock, W. Augener, S. Öhl, L. Nowicki, U. Raeth, K.H. Zurborn, A. Neiss, D. Messerer,

Immunodeficiency and Autoimmune Disorders

In the risk-adapted multicenter trial (02/84) for adult ALL the effectiveness of a consolidation therapy consisting of VM26 and Ara-C for high-risk patients was tested. Out of a total of 442 patients in the study, 79.2% achieved a complete remission. For the 182 high-risk patients the median remission duration is 17 months and the probability of being in continuous complete remission (CCR) is 34%. Improved results were found for elderly ALL patients between 35 and 65 years of age, whose median remission duration and CCR rate are 19 months and 40% respectively, compared to 15 months and 26% in the former study 01/81. The consolidation therapy has apparently also benefited patients with the immunological subtype c-ALL, for whom the CCR rate at 3 years is 53% in comparison to the previous value of 34%.